Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BTIG Reiterates Buy Rating on Adicet Bio Inc. (ACET)
August 14, 2024 6:11 AM EDTBTIG analyst Justin Zelin reiterated a Buy rating and $6.00 price target on Adicet Bio Inc. (NASDAQ: ACET).
The analyst comments "Adicet reported 2Q24 earnings, with expansion of ADI-001 autoimmune clinical development beyond lupus nephritis to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil... More
